Prevention of invasive bacterial diseases by immunization with polysaccharide-protein conjugates.
Covalent binding of CPS to T cell-dependent carrier proteins to form conjugates can be done by clinically acceptable methods. As a component of a conjugate, two immunologic properties of CPS are changed: 1) their immunogenicity is increased and; 2) reinjection induces a booster response in the young (T cell-dependence). Serum antibodies induced by the CPS alone, or as a component of a conjugate, are qualitatively similar: the difference between antibodies elicited by the CPS or the conjugate is quantitative. A clinical trial with a Hib-DT conjugate showed that conjugates could confer immunity in an age group not protected by the CPS alone. (table; see text) Induction of serum CPS antibodies confers protection against capsulated bacteria in the bloodstream: their role in the interaction of these pathogens on the mucous membranes has not been characterized. Preliminary in vitro experiments suggest that secretory antibodies to non-capsular structures may also exert protective immunity.
Robbins
J B
JB
Schneerson
R
R
Szu
S C
SC
Fattom
A
A
Yang
Y
Y
Lagergard
T
T
Chu
C
C
Sørensen
U S
US
D000818:Animals; D001424:Bacterial Infections / Q000517:prevention & control*; D001428:Bacterial Vaccines / Q000008:administration & dosage; D002352:Carrier Proteins / Q000008:administration & dosage / Q000276:immunology; D006801:Humans; D007114:Immunization; D009092:Mucous Membrane / Q000276:immunology; D011135:Polysaccharides, Bacterial / Q000008:administration & dosage / Q000276:immunology*
D001428:Bacterial Vaccines; D002352:Carrier Proteins; D011135:Polysaccharides, Bacterial